L.J.S. Drugs And Research Center Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-05-2024
- Paid Up Capital ₹ 0.10 M
as on 23-05-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 328.45%
(FY 2022)
- Profit 99.54%
(FY 2022)
- Ebitda 72.32%
(FY 2022)
- Net Worth -0.56%
(FY 2022)
- Total Assets 25.72%
(FY 2022)
About L.J.S. Drugs And Research Center
The Corporate was formerly known as L. J. S Drugs And Research Center Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Mishra and Abhay Mishra serve as directors at the Company.
- CIN/LLPIN
U24239MP2020PTC051797
- Company No.
051797
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Rewa, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at L.J.S. Drugs And Research Center?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Mishra  | Director | 12-Jul-2020 | Current |
| Abhay Mishra | Director | 12-Jul-2020 | Current |
Financial Performance of L.J.S. Drugs And Research Center.
L.J.S. Drugs And Research Center Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 328.45% increase. The company also saw a substantial improvement in profitability, with a 99.54% increase in profit. The company's net worth dipped by a decrease of 0.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of L.J.S. Drugs And Research Center?
Unlock access to L.J.S. Drugs And Research Center's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at L.J.S. Drugs And Research Center?
L.J.S. Drugs And Research Center has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of L.J.S. Drugs And Research Center, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped L.J.S. Drugs And Research Center's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
